ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Business deals

Novartis to buy Takeda's eyedrop unit for $5.3bn

Shire-owned business to be offloaded to focus on cancer drugs

TOKYO -- Takeda Pharmaceutical on Thursday said it will sell its dry-eye drug business to Swiss rival Novartis for up to $5.3 billion.

The Xiidra dry-eye medication business is owned by Shire, which Takeda bought for 6.2 trillion yen ($56.4 billion) in January.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more